patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_317378 | REC_0009701 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 4.5 | 66 | male | 1 | 48 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.3 | false | MSS | 2026-03-15T05:35:59.254221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571941 | REC_0009702 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 22 | 12.6 | 69 | female | 0 | 18 | 6.2 | 0 | sotorasib 960 mg daily | 28.2 | false | MSS | 2026-03-15T05:35:59.254469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824252 | REC_0009703 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 4.4 | 73 | female | 2 | 31 | 5.9 | 7 | pembrolizumab 200 mg q3w | 13.1 | false | MSS | 2026-03-15T05:35:59.254700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277025 | REC_0009704 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.5 | 77 | female | 2 | 7 | 6.5 | 1 | sotorasib 960 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:59.254945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633181 | REC_0009705 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 14.8 | 62 | male | 1 | 0 | 6.8 | 9 | sotorasib 960 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:59.255189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908045 | REC_0009706 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 5.3 | 79 | female | 1 | 16 | 3.3 | 2 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:59.255431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758555 | REC_0009707 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 16.9 | 76 | female | 1 | 18 | 5.2 | 2 | osimertinib 80 mg daily | 24.6 | false | MSI-H | 2026-03-15T05:35:59.255673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840252 | REC_0009708 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 11.9 | 74 | female | 1 | 25 | 4.8 | 2 | osimertinib 80 mg daily | 18 | true | MSS | 2026-03-15T05:35:59.255915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462235 | REC_0009709 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.1 | 60 | male | 0 | 14 | 5.7 | 5 | alectinib 600 mg BID | 15.1 | false | MSS | 2026-03-15T05:35:59.256198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332212 | REC_0009710 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 1.5 | 61 | male | 0 | 44 | 5.6 | 6 | pembrolizumab 200 mg q3w | 12.8 | true | MSS | 2026-03-15T05:35:59.256456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258423 | REC_0009711 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 31 | 6.5 | 59 | male | 0 | 19 | 3.6 | 0 | sotorasib 960 mg daily | 36.3 | false | MSS | 2026-03-15T05:35:59.256711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149974 | REC_0009712 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 10.4 | 78 | female | 1 | 16 | 5.7 | 5 | alectinib 600 mg BID | 8 | false | MSS | 2026-03-15T05:35:59.257050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970503 | REC_0009713 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 16.6 | 66 | male | 0 | 12 | 3.8 | 5 | osimertinib 80 mg daily | 21.2 | false | MSS | 2026-03-15T05:35:59.257312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976658 | REC_0009714 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 7.6 | 62 | female | 1 | 2 | 6.3 | 5 | entrectinib 600 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:59.257556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560338 | REC_0009715 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6.5 | 65 | female | 1 | 20 | 7.4 | 3 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:35:59.257810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770197 | REC_0009716 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 16.2 | 76 | male | 2 | 8 | 6.9 | 7 | sotorasib 960 mg daily | 7.3 | true | MSI-H | 2026-03-15T05:35:59.258071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579834 | REC_0009717 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 15.8 | 84 | female | 2 | 17 | 4.1 | 9 | osimertinib 80 mg daily | 17.5 | false | MSI-H | 2026-03-15T05:35:59.258319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505648 | REC_0009718 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 36 | 7.2 | 79 | female | 1 | 14 | 3.8 | 8 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.258576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889745 | REC_0009719 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.2 | 64 | male | 1 | 8 | 5.2 | 6 | alectinib 600 mg BID | 9.8 | true | MSI-H | 2026-03-15T05:35:59.258851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244975 | REC_0009720 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 8.5 | 65 | male | 1 | 10 | 5.4 | 2 | entrectinib 600 mg daily | 4.8 | true | MSS | 2026-03-15T05:35:59.259103+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104338 | REC_0009721 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 6.7 | 75 | female | 0 | 9 | 6.5 | 1 | sotorasib 960 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:59.259341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587386 | REC_0009722 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 17.3 | 78 | male | 1 | 18 | 5.7 | 7 | osimertinib 80 mg daily | 6.7 | true | MSS | 2026-03-15T05:35:59.259586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187206 | REC_0009723 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 13.6 | 84 | female | 2 | 17 | 3 | 2 | entrectinib 600 mg daily | 31.6 | true | MSI-H | 2026-03-15T05:35:59.259824+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844682 | REC_0009724 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 33 | 5.5 | 56 | female | 0 | 14 | 7.3 | 2 | pembrolizumab 200 mg q3w | 19.1 | false | MSS | 2026-03-15T05:35:59.260061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685890 | REC_0009725 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 16.9 | 84 | female | 0 | 11 | 3.8 | 1 | pembrolizumab 200 mg q3w | 24.8 | false | MSI-H | 2026-03-15T05:35:59.260556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114122 | REC_0009726 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.2 | 73 | female | 2 | 57 | 6.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:35:59.260801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653361 | REC_0009727 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 14.2 | 84 | female | 2 | 15 | 4.8 | 1 | sotorasib 960 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:59.261054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314547 | REC_0009728 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 7.2 | 66 | male | 1 | 17 | 5.1 | 8 | alectinib 600 mg BID | 10.8 | false | MSS | 2026-03-15T05:35:59.261292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123051 | REC_0009729 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 18.9 | 70 | male | 1 | 16 | 6 | 2 | alectinib 600 mg BID | 16.4 | false | MSS | 2026-03-15T05:35:59.261537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_595898 | REC_0009730 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 21.7 | 63 | male | 0 | 13 | 6.5 | 3 | osimertinib 80 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:59.261777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483640 | REC_0009731 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 12.8 | 66 | female | 1 | 22 | 2.8 | 2 | osimertinib 80 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:59.262011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213938 | REC_0009732 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 11.9 | 67 | female | 0 | 26 | 4.1 | 3 | sotorasib 960 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:59.262246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861088 | REC_0009733 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.9 | 68 | female | 1 | 46 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.7 | false | MSS | 2026-03-15T05:35:59.262480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955761 | REC_0009734 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 9.6 | 69 | female | 0 | 10 | 6 | 3 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.262727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925117 | REC_0009735 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 14.9 | 82 | female | 2 | 17 | 7.6 | 4 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:59.262988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275119 | REC_0009736 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 9.1 | 72 | female | 1 | 6 | 3.9 | 6 | entrectinib 600 mg daily | 10.3 | false | MSS | 2026-03-15T05:35:59.263234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164799 | REC_0009737 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7.7 | 76 | female | 0 | 79 | 4.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:35:59.263480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345288 | REC_0009738 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 10.2 | 61 | female | 0 | 16 | 6.3 | 2 | pembrolizumab 200 mg q3w | 26.8 | false | MSI-H | 2026-03-15T05:35:59.263894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_718417 | REC_0009739 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 15.8 | 79 | female | 2 | 17 | 2.9 | 1 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:59.264247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_642213 | REC_0009740 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 8.2 | 71 | female | 1 | 9 | 4.8 | 6 | sotorasib 960 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:59.264504+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967796 | REC_0009741 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 11.2 | 60 | male | 0 | 8 | 4.7 | 8 | entrectinib 600 mg daily | 8.5 | true | MSS | 2026-03-15T05:35:59.264752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424286 | REC_0009742 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 5.7 | 66 | female | 0 | 12 | 4.8 | 6 | alectinib 600 mg BID | 7.1 | true | MSS | 2026-03-15T05:35:59.264984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401448 | REC_0009743 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 25 | 6.8 | 71 | male | 2 | 47 | 5.5 | 0 | pembrolizumab 200 mg q3w | 28.2 | false | MSS | 2026-03-15T05:35:59.265218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928165 | REC_0009744 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 10.6 | 56 | female | 0 | 2 | 6.5 | 5 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.265457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409811 | REC_0009745 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 14.7 | 71 | male | 3 | 15 | 6.7 | 1 | alectinib 600 mg BID | 17.4 | true | MSS | 2026-03-15T05:35:59.265699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802120 | REC_0009746 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 22 | 14.9 | 77 | female | 2 | 21 | 5.6 | 0 | alectinib 600 mg BID | 20.2 | true | MSS | 2026-03-15T05:35:59.265937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344880 | REC_0009747 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 8.9 | 61 | female | 0 | 18 | 5 | 1 | entrectinib 600 mg daily | 16 | true | MSS | 2026-03-15T05:35:59.266171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735986 | REC_0009748 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 8.2 | 73 | female | 1 | 18 | 3.1 | 5 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:59.266399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524512 | REC_0009749 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.9 | 68 | female | 0 | 34 | 4.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.9 | true | MSS | 2026-03-15T05:35:59.266627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463322 | REC_0009750 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 7.4 | 60 | male | 0 | 31 | 4.5 | 2 | osimertinib 80 mg daily | 19 | true | MSS | 2026-03-15T05:35:59.266862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866987 | REC_0009751 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.1 | 62 | male | 1 | 9 | 5.7 | 4 | osimertinib 80 mg daily | 6.9 | true | MSS | 2026-03-15T05:35:59.267216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313489 | REC_0009752 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.4 | 66 | female | 1 | 33 | 6.5 | 7 | pembrolizumab 200 mg q3w | 12 | false | MSS | 2026-03-15T05:35:59.267469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503757 | REC_0009753 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 15.6 | 64 | male | 1 | 11 | 6.2 | 8 | osimertinib 80 mg daily | 9.6 | false | MSI-H | 2026-03-15T05:35:59.267726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844145 | REC_0009754 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 13.5 | 66 | male | 0 | 20 | 3.8 | 6 | entrectinib 600 mg daily | 11.1 | true | MSI-H | 2026-03-15T05:35:59.267974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418328 | REC_0009755 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 12 | 15.2 | 71 | female | 0 | 21 | 4.4 | 2 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.268274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856277 | REC_0009756 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 3 | 68 | female | 0 | 58 | 4.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.9 | false | MSS | 2026-03-15T05:35:59.268524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104502 | REC_0009757 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 15.2 | 81 | female | 2 | 12 | 6.3 | 4 | sotorasib 960 mg daily | 6.4 | false | MSS | 2026-03-15T05:35:59.268775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701648 | REC_0009758 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 7.6 | 78 | female | 2 | 57 | 6 | 2 | pembrolizumab 200 mg q3w | 13.1 | false | MSS | 2026-03-15T05:35:59.269014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774232 | REC_0009759 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.6 | 58 | male | 0 | 16 | 6.3 | 5 | sotorasib 960 mg daily | 8.1 | false | MSS | 2026-03-15T05:35:59.269269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809802 | REC_0009760 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.9 | 64 | male | 1 | 12 | 6.1 | 3 | sotorasib 960 mg daily | 5 | false | MSS | 2026-03-15T05:35:59.269524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733464 | REC_0009761 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 5.4 | 61 | female | 0 | 43 | 6.2 | 2 | pembrolizumab 200 mg q3w | 14 | false | MSS | 2026-03-15T05:35:59.269769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561133 | REC_0009762 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 31 | 6.1 | 73 | female | 0 | 20 | 3.6 | 2 | pembrolizumab 200 mg q3w | 12.6 | false | MSS | 2026-03-15T05:35:59.270021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951060 | REC_0009763 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 13.3 | 73 | female | 1 | 12 | 5.2 | 4 | entrectinib 600 mg daily | 13 | false | MSI-H | 2026-03-15T05:35:59.270271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587494 | REC_0009764 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 4 | 73 | male | 3 | 27 | 5.3 | 8 | pembrolizumab 200 mg q3w | 15.6 | false | MSS | 2026-03-15T05:35:59.270645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115909 | REC_0009765 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.6 | 70 | female | 2 | 6 | 7 | 9 | sotorasib 960 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:59.270915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267123 | REC_0009766 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 8.8 | 50 | male | 0 | 58 | 4.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 23.5 | true | MSS | 2026-03-15T05:35:59.271215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473302 | REC_0009767 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 18.5 | 69 | female | 0 | 17 | 5.7 | 2 | pembrolizumab 200 mg q3w | 9.9 | false | MSI-H | 2026-03-15T05:35:59.271469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819855 | REC_0009768 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 7 | 89 | male | 2 | 21 | 7.3 | 5 | entrectinib 600 mg daily | 7.4 | false | MSS | 2026-03-15T05:35:59.271720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109752 | REC_0009769 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 17.9 | 69 | female | 1 | 15 | 6.2 | 6 | osimertinib 80 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:59.271964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915375 | REC_0009770 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 15.6 | 74 | male | 1 | 9 | 3.6 | 5 | osimertinib 80 mg daily | 13.8 | false | MSI-H | 2026-03-15T05:35:59.272277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859196 | REC_0009771 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 17.1 | 70 | female | 2 | 15 | 5.9 | 2 | entrectinib 600 mg daily | 23.4 | false | MSI-H | 2026-03-15T05:35:59.272522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463181 | REC_0009772 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.2 | 69 | male | 1 | 61 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.7 | true | MSS | 2026-03-15T05:35:59.272765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485860 | REC_0009773 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.6 | 64 | female | 1 | 9 | 3.8 | 6 | osimertinib 80 mg daily | 7.4 | false | MSI-H | 2026-03-15T05:35:59.273007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872906 | REC_0009774 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 6.9 | 66 | female | 1 | 17 | 7.3 | 1 | entrectinib 600 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:59.273242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782505 | REC_0009775 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 8.1 | 74 | female | 1 | 8 | 3.8 | 1 | osimertinib 80 mg daily | 31.3 | false | MSS | 2026-03-15T05:35:59.273481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846418 | REC_0009776 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 12.7 | 68 | female | 0 | 18 | 5.9 | 5 | osimertinib 80 mg daily | 6.2 | false | MSI-H | 2026-03-15T05:35:59.273726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187599 | REC_0009777 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 11.6 | 76 | female | 2 | 18 | 8 | 1 | osimertinib 80 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:59.274093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332341 | REC_0009778 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 14.9 | 62 | male | 1 | 5 | 2.7 | 6 | sotorasib 960 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:59.274373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250999 | REC_0009779 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 6.1 | 80 | female | 1 | 41 | 6.2 | 5 | pembrolizumab 200 mg q3w | 11.3 | false | MSS | 2026-03-15T05:35:59.274622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937532 | REC_0009780 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 5.2 | 72 | female | 0 | 16 | 6.2 | 6 | osimertinib 80 mg daily | 15.3 | true | MSS | 2026-03-15T05:35:59.274931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498660 | REC_0009781 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 10.7 | 71 | female | 3 | 16 | 3.4 | 3 | entrectinib 600 mg daily | 7.1 | true | MSS | 2026-03-15T05:35:59.275181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696831 | REC_0009782 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 16 | 5 | 66 | female | 0 | 44 | 6.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 33.8 | true | MSS | 2026-03-15T05:35:59.275430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855578 | REC_0009783 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 4.9 | 81 | male | 1 | 51 | 5.8 | 7 | pembrolizumab 200 mg q3w | 12.9 | false | MSS | 2026-03-15T05:35:59.275682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574933 | REC_0009784 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 8.3 | 74 | male | 2 | 29 | 4.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.3 | false | MSS | 2026-03-15T05:35:59.275933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848603 | REC_0009785 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 7.6 | 73 | female | 1 | 1 | 4.8 | 5 | alectinib 600 mg BID | 12.3 | true | MSS | 2026-03-15T05:35:59.276223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150498 | REC_0009786 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 8.8 | 55 | female | 1 | 12 | 7.5 | 4 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.276477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737991 | REC_0009787 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 14.3 | 65 | male | 0 | 19 | 5.6 | 8 | entrectinib 600 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:59.276725+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697939 | REC_0009788 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 15 | 6.1 | 70 | female | 1 | 19 | 6.1 | 2 | entrectinib 600 mg daily | 29.3 | true | MSS | 2026-03-15T05:35:59.276958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345173 | REC_0009789 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 17.7 | 81 | male | 1 | 17 | 6.4 | 9 | sotorasib 960 mg daily | 16.2 | false | MSI-H | 2026-03-15T05:35:59.277206+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173275 | REC_0009790 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.8 | 71 | female | 2 | 59 | 6.5 | 3 | carboplatin + paclitaxel + pembrolizumab | 13.8 | true | MSS | 2026-03-15T05:35:59.277568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165737 | REC_0009791 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.2 | 61 | female | 1 | 38 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.2 | true | MSS | 2026-03-15T05:35:59.277863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610722 | REC_0009792 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 11.3 | 59 | female | 1 | 17 | 6.9 | 5 | alectinib 600 mg BID | 19.1 | true | MSI-H | 2026-03-15T05:35:59.278115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551520 | REC_0009793 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 9.5 | 72 | female | 1 | 4 | 6.3 | 2 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.278358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878861 | REC_0009794 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 5.4 | 83 | female | 3 | 55 | 7.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 9.8 | true | MSS | 2026-03-15T05:35:59.278603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392512 | REC_0009795 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 11.9 | 69 | female | 1 | 28 | 4.1 | 4 | pembrolizumab 200 mg q3w | 13.4 | true | MSI-H | 2026-03-15T05:35:59.278851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408549 | REC_0009796 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 10.8 | 72 | female | 2 | 21 | 4.9 | 5 | osimertinib 80 mg daily | 10.5 | true | MSI-H | 2026-03-15T05:35:59.279102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532824 | REC_0009797 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 11.6 | 68 | female | 0 | 16 | 5 | 4 | osimertinib 80 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:59.279357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341393 | REC_0009798 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 16 | 70 | female | 1 | 11 | 4.7 | 3 | entrectinib 600 mg daily | 20.9 | true | MSS | 2026-03-15T05:35:59.279615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999760 | REC_0009799 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 12.5 | 76 | female | 1 | 26 | 6.6 | 2 | osimertinib 80 mg daily | 23.4 | true | MSI-H | 2026-03-15T05:35:59.279887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446920 | REC_0009800 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 17.1 | 73 | female | 2 | 14 | 6.3 | 7 | entrectinib 600 mg daily | 6.4 | true | MSI-H | 2026-03-15T05:35:59.280252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.